Pediatric Tumor Panel
Test code: GDJ318
Related gene(s): ALK, APC, CDC73, DICER1, EPCAM, MEN1, MLH1, MSH2, MSH6, NF1, NF2, PHOX2B, PMS2, PRKAR1A, PTCH1, PTEN, RB1, RET, SMARCA4, SMARCB1, STK11, SUFU, TP53, TSC1, TSC2, VHL, WT1
The Pediatric Tumor Panel includes genes associated with increased risk for pediatric cancers/tumors, which includes brain cancer, thyroid cancer, renal cancer, and colorectal cancer. This panel may be appropriate for individuals who have clinical manifestations that are suggestive of an inherited childhood onset cancer syndrome.
- Colorectal Cancer
- Thyroid Cancer
- Renal Cancer
- Brain Cancer
- A personal or family history of cancer diagnosed at a particularly young age (such as rhabdomyosarcoma diagnosed under 3 years of age or thyroid cancer diagnosed in childhood)
- Multiple cancers in one person, either of the same origin (such as multiple brain tumors or bilateral renal tumors) or of different origins (such as medulloblastoma and basal cell carcinoma or adrenocortical carcinoma and sarcoma) with at least one diagnosis in childhood
- A personal or family history of certain cancers and/or benign tumors which are highly associated with a hereditary pediatric tumor syndrome (such as certain pediatric renal tumors or central nervous system tumors)
- Multiple relatives diagnosed with the same or related cancers on the same side of the family and spanning multiple generations
- Deletion/duplication analysis
- Next-Gen sequencing
- Preferred: 2-5 mL Blood – Lavender Top Tube
- Alternative: Buccal Swabs, Fibroblasts (separate charge for cell culture may apply)
- CPT code(s):* 81201×1, 81203×1, 81405×1, 81406×1, 81407×1
- Turnaround Time:** 3 weeks
*The CPT codes provided are based on AMA guidelines and are for informational purposes only. CPT coding is the sole responsibility of the billing party. Please direct any questions regarding coding to the payer being billed.
**Reporting times are typical and begin once the sample(s) are received at the GeneDx laboratory, but could be extended in situations outside GeneDx’s reasonable control.